RMD
ResMed Inc.
0
Dormant
ResMed's revenue growth stalls as margins surge amid Healthcare sector shifts.
The thesis
ResMed operates in the Healthcare sector with a revenue growth of 8.6% YoY and gross margin of 61.16%. The company's conviction score is 3/100, indicating a dormant state. Analyst consensus is HOLD with a P/E of 21.7x. High margins and stable revenue growth make it compelling.
Why now
The current macro context of escalating sanctions and geopolitical tensions may impact global supply chains, affecting ResMed's operations. The company's dormant conviction score suggests a potential for re-evaluation.
What to watch
ResMed's next quarter revenue growth and margin reports will indicate if the current trend continues. Geopolitical developments, particularly regarding Iran sanctions, will impact the company's operations and supply chain.
Key risks
Valuation risk is present with a P/E of 21.7x and DCF intrinsic value of $377. Execution risk is tied to maintaining high margins and revenue growth. Macro risk includes potential supply chain disruptions due to geopolitical tensions.
Theme exposure
Healthcare, Biotech & Devices
DirectResMed Inc. operates in medical - devices. That places it inside the Healthcare, Biotech & Devices story.
This brief is generated from our intelligence layers. Treat it as a starting point, not a final word.
Market intelligence only. Not financial advice. Not a recommendation.